| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10965907 | Vaccine | 2014 | 8 Pages |
Abstract
This trial tested for the first time an MVA-vectored candidate HIV-1 vaccine in HIV-1-exposed infants in Africa, demonstrating trial feasibility and vaccine safety, low immunogenicity, and compatibility with routine childhood vaccinations. These results are reassuring for use of the MVA vector in more potent prime-boost regimens.
Keywords
OPVZDVRecombinant modified vaccinia virus AnkaraModified vaccinia virus Ankara (MVA)DTXNVPPMTCTHEUEFV3TCTTXTDFIQREfavirenzTenofovirdiphtheria toxinAntiretroviral therapyZidovudineLamivudineLopinavir/ritonavirinterquartile rangeNevirapineARTHBVHibWAZOral polio vaccineWeight-for-age z-scoreHIV-1Human immunodeficiency virus type 1hepatitis B virus
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Irene N. Njuguna, Gwen Ambler, Marie Reilly, Beatrice Ondondo, Mercy Kanyugo, Barbara Lohman-Payne, Christine Gichuhi, Nicola Borthwick, Antony Black, Shams-Rony Mehedi, Jiyu Sun, Elizabeth Maleche-Obimbo, Bhavna Chohan, Grace C. John-Stewart,